The US Meals and Drug Administration (FDA) has accepted a capsule model of the weight-loss drug Wegovy, in accordance with pharmaceutical large Novo Nordisk.
It’s the first capsule of its sort to obtain approval from the regulator, marking a brand new period for weight-loss medicine.
Wegovy’s Danish makers Novo Nordisk stated the once-daily capsule was a “handy choice” to the injectable and would supply the identical weight reduction because the shot. It comes after Wegovy was accepted by the FDA particularly for weight reduction.
Others like Ozempic, which has related weight-loss results, have been primarily accepted for the therapy of Sort 2 diabetes.
The BBC has contacted the FDA for remark.
The Wegovy capsule confirmed a median weight lack of 16.6% throughout Novo Nordisk’s trials, the agency stated on Monday.
A 3rd of round 1,300 members skilled 20% or larger weight reduction in the identical trial, it added.
The capsule is predicted to be launched within the US in early January 2026.
“Sufferers could have a handy, once-daily capsule that may assist them lose as a lot weight as the unique Wegovy injection,” stated Mike Doustdar, the agency’s chief govt.
The capsule model of Wegovy may give Novo Nordisk’s gross sales a lift after a difficult yr which noticed its shares slide because it warned over its income.
The corporate has confronted intense competitors within the weight-loss market from rival drugmakers like Eli Lilly.
Novo Nordisk’s shares rose by virtually 10% in after-hours commerce in New York after the announcement.
